BWBridget K. Wagner

Bridget K. Wagner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bridget K. Wagner has a total of 253 co-authors. Here are the top co-authors by number of shared publications:

  • Stuart L. Schreiber

    Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, USA

    11 shared publications
  • Paul A. Clemons

    Chemical Biology and Therapeutics Science Program, Broad Institute

    9 shared publications
  • Morten Lundh

    Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    5 shared publications
  • Vlado Dančík

    Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, USA

    5 shared publications
  • Amedeo Vetere

    Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA

    4 shared publications
  • Amedeo Vetere

    Department of Biochemistry, Biophysics and Macromolecular Chemistry, University of Trieste, Italy

    4 shared publications

Latest Publications

  • KD025 Is a Casein Kinase 2 Inhibitor That Protects Against Glucolipotoxicity in β-Cells

    by Ranjan Devkota, Jonnell C. Small, Kaycee Carbone, Michael A. Glass, Amedeo Vetere, Bridget K. Wagner

    Glucolipotoxicity (GLT), in which elevated levels of glucose and fatty acids have deleterious effects on β-cell biology, is thought to be one of the major contributors in progression of type 2 diabetes. In search of novel small molecules that protect β-cells against GLT, we previously discovered KD025, an inhibitor of Rho-associated coiled-coil–containing kinase isoform 2 (ROCK2), as a GLT-protective compound in INS-1E cells and dissociated human islets. To further understand the mechanism of action of KD025, we found that pharmacological and genetic inhibition of ROCK2 was not responsible for the protective effects of KD025 against GLT. Instead, kinase profiling revealed that KD025 potently inhibits catalytic subunits of casein kinase 2 (CK2), a constitutively active serine/threonine kinase. We experimentally verified that the inhibition of one of the catalytic subunits of casein kinase 2, CK2A1, but not CK2A2, improved cell viability when challenged with GLT. We conclude that KD025 inhibits CK2 to protect β-cells from GLT. Article Highlights:


  • Top Cited Papers
    Open Access

    Predicting compound activity from phenotypic profiles and chemical structures

    by Nikita Moshkov, Tim Becker, Kevin Yang, Peter Horvath, Vlado Dancik, Bridget K. Wagner, Paul A. Clemons, Shantanu Singh, Anne E. Carpenter, Juan C. Caicedo

    Predicting assay results for compounds virtually using chemical structures and phenotypic profiles has the potential to reduce the time and resources of screens for drug discovery. Here, we evaluate the relative strength of three high-throughput data sources—chemical structures, imaging (Cell Painting), and gene-expression profiles (L1000)—to predict compound bioactivity using a historical collection of 16,170 compounds tested in 270 assays for a total of 585,439 readouts. All three data modalities can predict compound activity for 6–10% of assays, and in combination they predict 21% of assays with high accuracy, which is a 2 to 3 times higher success rate than using a single modality alone. In practice, the accuracy of predictors could be lower and still be useful, increasing the assays that can be predicted from 37% with chemical structures alone up to 64% when combined with phenotypic data. Our study shows that unbiased phenotypic profiling can be leveraged to enhance compound bioactivity prediction to accelerate the early stages of the drug-discovery process.


  • Open Access

    Reference compounds for characterizing cellular injury in high-content cellular morphology assays

    by Jayme L. Dahlin, Bruce K. Hua, Beth E. Zucconi, Shawn D. Nelson, Shantanu Singh, Anne E. Carpenter, Jonathan H. Shrimp, Evelyne Lima-Fernandes, Mathias J. Wawer, Lawrence P. W. Chung, et al.

    Robust, generalizable approaches to identify compounds efficiently with undesirable mechanisms of action in complex cellular assays remain elusive. Such a process would be useful for hit triage during high-throughput screening and, ultimately, predictive toxicology during drug development. Here we generate cell painting and cellular health profiles for 218 prototypical cytotoxic and nuisance compounds in U-2 OS cells in a concentration-response format. A diversity of compounds that cause cellular damage produces bioactive cell painting morphologies, including cytoskeletal poisons, genotoxins, nonspecific electrophiles, and redox-active compounds. Further, we show that lower quality lysine acetyltransferase inhibitors and nonspecific electrophiles can be distinguished from more selective counterparts. We propose that the purposeful inclusion of cytotoxic and nuisance reference compounds such as those profiled in this resource will help with assay optimization and compound prioritization in complex cellular assays like cell painting.


  • A general approach to identify cell-permeable and synthetic anti-CRISPR small molecules

    by Donghyun Lim, Qingxuan Zhou, Kurt J. Cox, Benjamin K. Law, Miseon Lee, Praveen Kokkonda, Vedagopuram Sreekanth, Rajaiah Pergu, Santosh K. Chaudhary, Soumyashree A. Gangopadhyay, et al.

    The need to control the activity and fidelity of CRISPR-associated nucleases has resulted in a demand for inhibitory anti-CRISPR molecules. The small-molecule inhibitor discovery platforms available at present are not generalizable to multiple nuclease classes, only target the initial step in the catalytic activity and require high concentrations of nuclease, resulting in inhibitors with suboptimal attributes, including poor potency. Here we report a high-throughput discovery pipeline consisting of a fluorescence resonance energy transfer-based assay that is generalizable to contemporary and emerging nucleases, operates at low nuclease concentrations and targets all catalytic steps. We applied this pipeline to identify BRD7586, a cell-permeable small-molecule inhibitor of SpCas9 that is twofold more potent than other inhibitors identified to date. Furthermore, unlike the reported inhibitors, BRD7586 enhanced SpCas9 specificity and its activity was independent of the genomic loci, DNA-repair pathway or mode of nuclease delivery. Overall, these studies describe a general pipeline to identify inhibitors of contemporary and emerging CRISPR-associated nucleases.


  • Open Access

    Reference compounds for characterizing cellular injury in high-content cellular morphology assays

    by Jayme L. Dahlin, Bruce K. Hua, Beth E. Zucconi, Shawn D. Nelson, Shantanu Singh, Anne E. Carpenter, Jonathan H. Shrimp, Evelyne Lima-Fernandes, Mathias J. Wawer, Lawrence P.W. Chung, et al.

    Robust, generalizable approaches to identify compounds efficiently with undesirable mechanisms of action in complex cellular assays remain elusive. Such a process would be useful for hit triage during high-throughput screening and, ultimately, predictive toxicology during drug development. We generated cell painting and cellular health profiles for 218 prototypical cytotoxic and nuisance compounds in U-2 OS cells in a concentration-response format. A diversity of compounds causing cellular damage produced bioactive cell painting morphologies, including cytoskeletal poisons, genotoxins, nonspecific electrophiles, and redox-active compounds. Further, we show that lower quality lysine acetyltransferase inhibitors and nonspecific electrophiles can be distinguished from more selective counterparts. We propose that the purposeful inclusion of cytotoxic and nuisance reference compounds such as those profiled in this Resource will help with assay optimization and compound prioritization in complex cellular assays like cell painting.

  • Open Access

    Phenotypic Screening for Small Molecules that Protect β-Cells from Glucolipotoxicity

    by Jonnell C. Small, Aidan Joblin-Mills, Kaycee Carbone, Maria Kost-Alimova, Kumiko Ayukawa, Carol Khodier, Vlado Dancik, Paul A. Clemons, Andrew B. Munkacsi, Bridget K. Wagner

    Type 2 diabetes is marked by progressive β-cell failure, leading to loss of β-cell mass. Increased levels of circulating glucose and free fatty acids associated with obesity lead to β-cell glucolipotoxicity. There are currently no therapeutic options to address this facet of β-cell loss in obese type 2 diabetes patients. To identify small molecules capable of protecting β-cells, we performed a high-throughput screen of 20,876 compounds in the rat insulinoma cell line INS-1E in the presence of elevated glucose and palmitate. We found 312 glucolipotoxicity-protective small molecules (1.49% hit rate) capable of restoring INS-1E viability, and we focused on 17 with known biological targets. 16 of the 17 compounds were kinase inhibitors with activity against specific families including but not limited to cyclin-dependent kinases (CDK), PI-3 kinase (PI3K), Janus kinase (JAK), and Rho-associated kinase 2 (ROCK2). 7 of the 16 kinase inhibitors were PI3K inhibitors. Validation studies in dissociated human islets identified 10 of the 17 compounds, namely, KD025, ETP-45658, BMS-536924, AT-9283, PF-03814735, torin-2, AZD5438, CP-640186, ETP-46464, and GSK2126458 that reduced glucolipotoxicity-induced β-cell death. These 10 compounds decreased markers of glucolipotoxicity including caspase activation, mitochondrial depolarization, and increased calcium flux. Together, these results provide a path forward toward identifying novel treatments to preserve β-cell viability in the face of glucolipotoxicity.


  • Open Access

    Emerging diabetes therapies: Bringing back the β-cells

    by G. Basile, M.M.F. Qadir, F. Mauvais-Jarvis, A. Vetere, V. Shoba, A.E. Modell, R.L. Pastori, H.A. Russ, B.K. Wagner, J. Dominguez-Bendala


  • Open Access

    Computational repurposing of therapeutic small molecules from cancer to pulmonary hypertension

    by Vinny Negi, Jimin Yang, Gil Speyer, Andres Pulgarin, Adam Handen, Jingsi Zhao, Yi Yin Tai, Ying Tang, Miranda K. Culley, Qiujun Yu, et al.

    A network dependency platform was generated to define a landscape of cancer drug mechanisms in pulmonary hypertension.